Understanding the Effects of Non-Invasive Transauricular Vagus Nerve Stimulation on EEG and HRV

Summary

This protocol provides information on how to apply transcutaneous auricular vagus nerve stimulation (taVNS) in a clinical trial, including potential biomarkers such as EEG metrics and heart rate variability (HRV) to measure the effect of this treatment on the autonomic nervous system.

Abstract

Several studies have demonstrated promising results of transcutaneous auricular vagus nerve stimulation (taVNS) in treating various disorders; however, no mechanistic studies have investigated this technique's neural network and autonomic nervous system effects. This study aims to describe how taVNS can affect EEG metrics, HRV, and pain levels. Healthy subjects were randomly allocated into two groups: the active taVNS group and the sham taVNS group. Electroencephalography (EEG) and Heart Rate Variability (HRV) were recorded at baseline, 30 min, and after 60 min of 30 Hz, 200-250 µs taVNS, or sham stimulation, and the differences between the metrics were calculated. Regarding vagal projections, some studies have demonstrated the role of the vagus nerve in modulating brain activity, the autonomic system, and pain pathways. However, more data is still needed to understand the mechanisms of taVNS on these systems. In this context, this study presents methods to provide data for a deeper discussion about the physiological impacts of this technique, which can help future therapeutic investigations in various conditions.

Introduction

Transauricular vagus nerve stimulation (taVNS) is a recent neuromodulation technique that does not require surgery and utilizes a non-invasive stimulation device placed at the concha or tragus of the ear. Consequently, it is more accessible and safer for patients¹. In recent years, the taVNS field has rapidly expanded, primarily focusing on clinical trials demonstrating potential therapeutic advantages for various pathological conditions, including epilepsy, depression, tinnitus, Parkinson's disease, impaired glucose tolerance, schizophrenia, and atrial fibrillation². There is much to discuss about taVNS and its effects on biological processes in the central and peripheral systems. Ideally, a biological marker might demonstrate that the auricular branch of the vagus was stimulated, affecting intracranial structures and allowing researchers to analyze how taVNS affects physiological function. Nevertheless, without a trustworthy biomarker, it is not easy to understand what the taVNS data mean and how to interpret them effectively.

Electroencephalography (EEG) is an encouraging imaging tool to provide biomarkers for taVNS. It is a non-invasive, reliable, inexpensive approach to measure and quantify cortical activity^3,4. Following this process, our group performed a systematic review, demonstrating elementary details that taVNS could influence cortical activity, mainly increasing EEG power spectrum activity in lower frequencies (delta and theta). However, diverse results in higher frequencies (alpha) and changes in early ERP components related to inhibitory tasks were also detected. High heterogeneity between the studies was found; therefore, more homogeneous, more significant, and well-planned studies are essential to make more robust conclusions about the effects of taVNS on brain activity measured by EEG³. Assessing EEG during taVNS could advance future research on integrating the two techniques for a mobile, closed-loop, monitoring, and non-invasive stimulation tool to affect brain oscillatory activity⁴.

Alpha asymmetry, which assesses the relative alpha band activity between the brain hemispheres, particularly at frontal electrodes, is a frequently researched EEG biomarker. Previous literature has used this biomarker to analyze the approach-withdraw hypothesis^5,6, which holds that the right frontal side of the brain is associated with withdrawal behaviors. In contrast, the left frontal side is associated with approach behaviors. Since alpha is associated with low brain activity, an increase in alpha on the left side of the brain suggests lower activity and may show a lack of approach behavior. This concept helps to explain some results in the alpha band at the left side hemisphere in depressed patients⁷. Additionally, EEG electrodes record the activity of neuronal populations, examining Functional Connectivity (FC) or changes in large-scale brain networks, such as the default mode network (DMN)^7,8.

Based on that, quantitative electroencephalography can be employed to assess the effects of taVNS on brain activity; however, more studies are required to systematically demonstrate the specific metrics and effects that would highlight the non-invasive stimulation through the auricular branch of the vagus nerve.

Peripherally, the vagus nerve and sympathetic nervous system mediate the heart's contractile and electrical function⁹. This regulation promotes the heart's pacemaker ability and controls it through physiological manifestations of the body, known as sinus depolarizations. Heart rate variability (HRV) records the changes per beat of sinus depolarization, thus non-invasively describing vagal influences on the sinus node¹⁰. Given this function, HRV has been seen and studied as a prominent neurocardiac function biomarker associated with an individual's well-being and the likelihood of morbidity, mortality, and stress^11,12.

In the context of taVNS, HRV has been recorded in many trials, and stimulation has been thought to modulate HRV^9,11,12. Considering that decreased HRV has been related to the morbidity and mortality of different diseases through mechanisms such as over-activity of the sympathetic nervous system, inflammatory response, and oxidative stress, the vagal nerve modulation of taVNS is thought to directly impact HRV and its sinus regulation^13,14. In fact, some trials have already indicated that taVNS can increase HRV in healthy subjects, thus supporting this hypothesis^15,16. However, there is still a need to understand better whether different taVNS parameters can affect HRV differently.

Currently, no mechanistic studies have investigated the taVNS neural network and autonomic nervous system effects of this technique together. Therefore, this protocol aims to assess how taVNS can affect EEG metrics and HRV and evaluate its safety. Additionally, this also aims to identify predictors that can influence the response to taVNS. Understanding the variables associated with the response to taVNS can help design future clinical trials to maximize the effects of this intervention.

Protocol

All study procedures were performed at the Spaulding Neuromodulation Center/Spaulding Cambridge Hospital. Ethical approval for this protocol was obtained from Mass General Brigham IRB (Number Protocol #:2022P003200). Informed consent was obtained from all subjects using the encrypted Research Electronic Data Capture (REDCap) platform (see Table of Materials). Trial registration number: NCT05801809.

1. Subject selection and screening

1. Identify potential subjects by several sources.
   NOTE: For the present study, the human subjects were identified from (1) flyers in public areas across the Boston-land region, (2) internet and newspaper advertisements, (3) advertisements posted on public transportation (The T), (4) Via the Rally platform by Mass General Brigham Research (see Table of Materials). Forty-four healthy subjects were selected for the present study.
2. Contact eligible subjects or ask permission electronically to contact them to provide more information about the study.
3. At the first point of contact (usually a phone call or Zoom Enterprise call), a study co-investigator administers an online pr-screening questionnaire. Once the online pre-screening process is completed, take the information gathered by the co-investigator to the PI of the study for further review to confirm eligibility. Then, store the data obtained from the pre-screening in an encrypted web-based platform (REDCap, see Table of Materials).
   1. Include subjects older than 18 years and naive to the stimulation (taVNS).
   2. Exclude pregnant women, the presence of medical conditions, and presence of any contraindication to transauricular vagus nerve stimulation.

2. Equipment details

1. Use a Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) device (Figure 1), which consists of an earset (Figure 2) with conductive ear tips placed on the auricular concha of the ears (Figure 3).
2. Connect the electrodes to a stimulator, and during active stimulation, stimulate both the cymbal conchae of the auricular at 30 Hz, 200-250 µs, for 60 min.
   NOTE: For the commercial details of the device and the related accessories, please see Table of Materials.

3. taVNS procedure

NOTE: The protocol consists of two visits: Visit 1 (consent, screening, and collection of demographics information), and Visit 2 (assessments and intervention). The flow of the study can be found in Figure 4.

1. On Visit 2, randomize the subjects to receive the intervention.
   NOTE: The active group receives active taVNS, and the sham group receives sham taVNS.
2. Blind the subjects, intervention team (co-investigators/ CO-Is who performed the taVNS intervention), and outcome assessors (CO-Is who performed the assessments or analyzed the data) during the trial. Ensure that one non-involved staff member will generate the allocation sequence, seal the envelopes, and randomly assign individuals to interventions using external and visual display identical devices that differ on whether they are active (active current) or not (sham) by another staff member who is not involved in data collection or analysis.
3. Collect the data for this study from subjects using an electronic format capture system (REDCap). The following assessments performed are displayed in Table 1.
4. When the subject arrives, provide information regarding the procedure. First, assess the pain levels and pain modulation, using heat stimuli on the right forearm for the pain threshold, and cold water for the Conditioned Pain Modulation (CPM), following the adapted protocol suggested by Granot¹⁷ and Nirl¹⁸.
   1. First, determine the pain-60 test temperature (temperature that instigates pain experience at a magnitude of 60 on a 60-100 NPS) by applying a Peltier thermode (see Table of Materials) on the right forearm of subjects and deliver short heat stimuli (41-48 °C), each temperature lasting for 7 s starting from the time the stimulus intensity reaches the destination temperature.
   2. Ask the subjects to rate the level of pain intensity using a numerical pain scale (NPS) ranging from 0 = ''no pain'' to 100 = ''the worst pain imaginable''.
   3. Once the pain-60 temperature is determined, administer the test stimulus by applying the same for 30 s at that temperature, and ask the subjects to rate their levels of pain intensity 3 times: at 10 s, 20 s, and 30 s after the thermode reaches the pain-60 temperature (mean scores of the three pain rating will be calculated).
   4. 5 min after delivering the test stimulus, immerse the left hand of the subject in a bath of water set at 10 °C to 12 °C for 30 s for the conditioned stimulus. Then, apply the same pain-60 temperature on the right forearm of the subject (left hand will still be immersed) for 30 s and again ask the subject to rate their levels of pain intensity 3 times after the thermode reaches the pain-60 temperature: at 10 s, 20 s and 30 s.
      NOTE: CPM (Conditioned Pain Modulation) response will be calculated as the difference between the average of pain ratings from the test stimulus minus the average of pain ratings during the conditioned stimulus.
5. Ask subjects to place an HRV monitor (displayed in Figure 5 and Figure 6).
6. Next, assess baseline HRV for 5 min (to analyze frequency HF, LF, LF/HF, and time domains metrics) recording with the monitor connected by Bluetooth to a tablet.
7. Set up the EEG connected to a computer system, and start the assessments (resting and task-related), which lasts about 30 min.
8. Next, set up the taVNS device.
   1. Examine, clean with a 70% alcohol pad, and prepare the ear skin of the subject to place the electrodes.
   2. Next, apply the saline solution to the eatips, place the electrodes on the ear, and start the stimulation, which lasts 60 min.
9. When the taVNS reaches 30 min, record HRV and EEG again for 5 min only.
10. After 60 min of stimulation, assess the subject for EEG, HRV, and pain, and repeat the pretrial procedures (as mentioned below):
    1. Perform EEG and HRV assessment, which lasts about 30 min.
    2. Perform CPM assessment following step 3.4.
11. Perform assessments regarding side effects, fatigue and mood.
12. Complete the session.

4. Follow up procedures

1. After randomizing the subjects and completing the data collection, perform data analysis³.

Results

We performed a preliminary descriptive analysis of the first randomized subject without unblinding the study. For this reason, which arms this subject was allocated to is unknown. The first subject is a 69-year-old woman, non-Hispanic, Caucasian, with a college degree, who did not report any adverse event during or after the stimulation session. The clinical data are displayed in Table 2.

Besides, a topographic distribution of scalp plots was created in resting-state EEG for t...

Discussion

Transauricular Vagus Nerve Stimulation (taVNS) is emerging as a promising therapeutic avenue for addressing several neuropsychiatric conditions. Mood disorders, such as depression and anxiety, pose a significant global health burden, especially after the COVID-19 pandemic¹⁹. Recent studies exploring taVNS have exhibited the potential to alleviate symptoms associated with these disorders.

The vagus nerve plays a pivotal role in the brain-gut axis and the regulation of e...

Materials

Name	Company	Catalog Number	Comments
Articulated arm	Electrical Geodesics, Inc.	20090645
Baby shampoo	Dynarex	1396
Charge Cable	NEURIVE Co.	HV12303003
Computer	Apple	YM92704U4PC
Condutive eartip	NEURIVE Co.	HV12303003
Earset	NEURIVE Co.	HV12303003
EEG 64-channel cap	Electrical Geodesics, Inc.	H11333
Heart rate sensor	Polar	M311370175396
Monitor	Dell	REVA01
Net Amps 300	Electrical Geodesics, Inc.	A09370244
Peltier thermode	Advanced Medical Systems, Ramat Yishai, Isreal
Potassium Chloride (dry)	Electrical Geodesics, Inc.	820127755
Rally	Mass General Brigham Research		online platform
Research Electronic Data Capture (REDCap)	Vanderbilt		web-based software platform
Thermosensory Stimulator	Medoc Ltd	1241
Transauricular vagus nerve stimulator	NEURIVE Co.	HV12303003